Background/aims: The Food and Drug Administration Amendments Act mandates that applicable clinical trials report basic summary results to the ClinicalTrials.gov database within 1 year of trial completion or termination. We aimed to determine the proportion of pulmonary trials reporting basic summary results to ClinicalTrials.gov and assess factors associated with reporting. Methods: We identified pulmonary clinical trials subject to the Food and Drug Administration Amendments Act (called highly likely applicable clinical trials) that were completed or terminated between 2008 and 2012 and reported results by September 2013. We estimated the cumulative percentage of applicable clinical trials reporting results by pulmonary disease category. Multivariable Cox regression modeling identified characteristics independently associated with results reporting. Results: Of 1450 pulmonary highly likely applicable clinical trials, 380 (26%) examined respiratory neoplasms, 238 (16%) asthma, 175 (12%) chronic obstructive pulmonary disease, and 657 (45%) other respiratory diseases. Most (75%) were pharmaceutical highly likely applicable clinical trials and 71% were industry-funded. Approximately 15% of highly likely applicable clinical trials reported results within 1 year of trial completion, while 55% reported results over the 5-year study period. Earlier phase highly likely applicable clinical trials were less likely to report results compared to phase 4 highly likely applicable clinical trials (phases 1/2 and 2 (adjusted hazard ratio 0.41 (95% confidence interval: 0.31-0.54)), phases 2/3 and 3 (adjusted hazard ratio 0.55 (95% confidence interval: 0.42-0.72)) and phase not applicable (adjusted hazard ratio 0.43 (95% confidence interval: 0.29-0.63)). Pulmonary highly likely applicable clinical trials without Food and Drug Administration oversight were less likely to report results compared with those with oversight (adjusted hazard ratio 0.65 (95% confidence interval: 0.51-0.83)). Conclusion: A total of 15% of pulmonary clinical highly likely applicable clinical trials report basic summary results to ClinicalTrials.gov within 1 year of trial completion. Strategies to improve reporting are needed within the pulmonary community.
Background/aims
As of January 2017, National Institutes of Health (NIH) has mandated that all clinical studies with more than one human subject and receiving partial or complete NIH funding report basic summary results to the ClinicalTrials.gov database within 1 year of completion or termination. Failure to comply can result in penalties such as loss of funding and a $10,000 fine per day of noncompliance. 1, 2 The NIH policy will cover all forms of biomedical and health-related outcome research including interventional, observational, and feasibility studies. The NIH policy is an extension of the 2007 Food and Drug Administration Amendments Act that mandated that ''applicable clinical trials'' report basic summary results (i.e. participant flow, baseline characteristics, outcomes measures and adverse events) to the database, within 1 year of trial completion or termination. [3] [4] [5] ''Applicable Clinical Trials'' were limited to all non-phase I interventional studies evaluating biologics, drugs, or devices, with at least one study site in the United States, or investigational drug or device trials. 6, 7 Public reporting of clinical trial results promotes transparency in clinical research. 3, 6, [8] [9] [10] [11] In 2000, the ClinicalTrials.gov database was created as a registry of interventional trials. In 2007, mandatory reporting was introduced to reduce reporting and publication bias, promote efficient allocation of research dollars, and fulfill the ethical obligation to use clinical research results to contribute to our field of knowledge. 4, [11] [12] [13] [14] [15] A recent study noted that only 13.4% of all applicable clinical trials completed between 2008 and 2012 reported results within 1 year of completion or termination while 38.3% reported results any time during the 5-year study period. 16 Nguyen et al. found that 9% of phase II or IV cancer drug trials from 2007 to 2010 reported results within 1 year and 31% within 3 years. 17, 18 However, the extent to which pulmonary applicable clinical trials report summary results is currently unknown. 19 We sought to determine the proportion of applicable clinical trials in pulmonary medicine reporting basic summary results to the ClinicalTrials.gov database and assess factors independently associated with results reporting to inform future implementation strategies.
Methods

Data sources
We identified pulmonary trials likely subject to the Food and Drug Administration Amendments Act, called highly likely applicable clinical trials (HLACTs), using an algorithm based on input from the National Library of Medicine. 16 The details of the HLACT algorithm were previously reported, and the algorithm steps are outlined in supplement Table E1 . 16 In brief, we included all registered trials (n = 152,611) between 1 January 2008 and 27 September 2013. We excluded trials that did not meet criteria for an applicable clinical trial. 16, 20 Additionally, we excluded trials with a ''withdrawn'' status (i.e. study stopped prior to enrollment of first participant) or a completion date prior to December 2007, which was before enactment of the Food and Drug Administration Amendments Act. After exclusions, 32,656 clinical trials were identified as HLACTs. We further restricted analysis to HLACTs that were completed or terminated between 1 January 2008 and 31 August 2012 to allow an opportunity to report within 1 year of study end date.
Validation of HLACT algorithm
Anderson et al. 16 confirmed the accuracy of the HLACT algorithm by manually reviewing a random sample of 205 HLACTs and 100 non-HLACTs at high risk for being misclassified. They published the details of their manual review in their original manuscript and the corresponding online supplement. In brief, two reviewers (M.L.A. and R.C.) independently reviewed a sample of HLACT and non-HLACT trials to determine whether they were applicable clinical trials and required to report results. Based on the experience of ClinicalTrials.gov staff reviewing the accuracy of trial registration records, Anderson et al. 16 learned that trials at highest risk for being misclassified as nonHLACTs are those that incorrectly reported that their study did not involve a Food and Drug Administration (FDA)-regulated intervention type (personal communication, Dr Zarin, 10/10/2014). So Anderson et al. sampled trials not identified as HLACTs, targeting studies that did not list their intervention as a drug, device, biologic, genetic or radiation. During manual review, they determined whether these studies did actually use an FDA-regulated medical product.
The methods for evaluating trials for HLACT status were confirmed by Dr Deborah Zarin and Tony Tse at ClincialTrials.gov. Discrepancies were resolved by group consensus. Of the 205 HLACTs, they found 2 that were not applicable clinical trials and estimated that 4-9 were probably not HLACTs. Of the 100 nonHLACTs, 16-19 trials were actually HLACTs due to the trial sponsors not correctly identifying the intervention type.
Anderson et al. also determined the number of HLACTs that were not legally required to report results. A study sponsor could delay the 12-month deadline for results reporting for several reasons including submitting a ''certification of initial use'' if the medication product was not approved for market, ''certification of new use'' if the sponsor intended to see approval of a new use of an approved product, or an extension to delay result for a good cause. Data on trials that submitted certification or extension requests to ClinicalTrials.gov were provided by the National Library of Medicine. These trials are still considered applicable clinical trials, and therefore correctly identified by the algorithm, but are not legally required to report results because they submitted a certificate or extension request. 16 
Identification of pulmonary HLACTs
To identify pulmonary HLACTs, we used medical subject headings terms, which are annotations generated by the National Library of Medicine or study personnel. Pulmonary terms were categorized under the major medical subject headings' tree heading of ''respiratory tract diseases,'' and a study was included if at least one medical subject headings' term was a respiratory tract disease found in the conditions provided by study personnel or in medical subject headings' annotations generated by the National Library of Medicine (online supplement Table E2 ). 21 A pulmonologist (I.L.R.) reviewed terms for relevance and categorized into disease categories, including respiratory neoplasm, asthma, chronic obstructive pulmonary disease, and other (online supplement Table E3 ). Categorization of medical subject headings' terms was confirmed by a second pulmonologist (L.G.Q.). For HLACTs with more than one pulmonary condition identified, we categorized each study into mutually exclusive categories to minimize overlap of conditions according to the following hierarchical order: respiratory neoplasm, asthma, chronic obstructive pulmonary disease, and other.
Characterizing clinical HLACTs
We characterized HLACTs according to their primary purpose, intervention group (i.e. biologic, drug, device, other), phase, FDA oversight authority, funding source, enrollment size, recruitment status, study duration, year of study completion, number of arms, presence of randomization, presence of masking, and disease group (i.e. neoplasm, asthma, chronic obstructive pulmonary disease, other). 7, 16, 22, 23 Table E4 in the online supplement contains additional descriptions of trial characteristics.
Outcomes
Our principal outcomes were occurrence of HLACTs' summary results being reported in ClinicalTrials.gov within 1 year of HLACT completion or termination and time to reporting of HLACT summary results during our 5-year observation period (1 January 2008 to 27 September 2013). In accordance with the Federal Drug Administration and Amendment Act, we considered HLACTs to have reported results if they recorded at least one basic summary result in the database. According to the Federal Drug Administration Amendment Act, reporting results in a peer-reviewed journal is not considered fulfillment of federal results reporting requirements. We defined a HLACT's time to reporting results as the number of months between the HLACT's primary completion date or termination date and the date HLACT results were first uploaded into the database. 16 
Statistical analysis
We described HLACTs according to disease categories. We used Kaplan-Meier curves to estimate cumulative percentage of HLACTs reporting results within 1 year and 5 years. We stratified Kaplan-Meier curves by disease category. We compared disease category KaplanMeier curves using log-rank test. We constructed multivariable Cox regression models to identify factors independently associated with reporting results. We constructed models that contained phase, oversight, funding source, enrollment, disease group, primary purpose, intervention group, HLACTs' status (i.e. completed or terminated), study duration, number of arms, use of randomization, masking, and primary completion year. All p-values were two-sided. We did not adjust for multiple comparisons. An aim of this study was to evaluate whether there were time trends in the reporting of results to ClinicalTrials.gov for pulmonary trials, and whether these trends were similar across disease groups. To address this aim, we performed interaction testing to evaluate the relationship between disease group and study completion year. Of factors included in the Cox regression model, only total enrollment had missing values with 1.2% missing. We excluded missing values from the analysis. All analyses were performed at Duke Clinical Research Institute using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Pulmonary HLACT characteristics
We identified 13,327 HLACTs in ClinicalTrials.gov. We excluded a majority (n = 11,877) because they were non-pulmonary HLACTs (Figure 1 ). Of 1450 pulmonary HLACTs, 74.9% were drug HLACTs, 14.9% were studies of biologics, and 8.6% were device HLACTs. Most of the studies were funded by industry and 60.1% were conducted only in the United States. The majority of pulmonary HLACTs were classified as ''other respiratory conditions,'' 26% focused on respiratory neoplasms, 16% on asthma, and 12% on chronic obstructive pulmonary disease. The median enrollment for pulmonary HLACTs was 98 subjects (interquartile range (IQR): 34-339) and median study duration was 21 months (IQR: 9-38). Most pulmonary HLACTs were randomized double-blinded (76.7%) and included at least two arms (75%). Pulmonary HLACT phases were diverse with 7% phase 1/2, 40% phase 2, 2% phase 2/3, 26% phase 3, 13% phase 4, and 11% not applicable (N/A; Table 1 ). See online supplemental Table E5 for additional pulmonary HLACT characteristics.
Occurrence and timing of pulmonary HLACTs reporting results
A total of 619 pulmonary HLACTs reported results over the 5-year study period, reflecting a cumulative percentage of 55.1% by 5 years for all pulmonary HLACTs. By disease group, 45.3% respiratory neoplasm HLACTs, 50.6% asthma HLACTs, 62.6% of chronic obstructive pulmonary disease HLACTs, and 59.8% of other pulmonary HLACTs reported results within the 5-year study period (Figure 2 ). Approximately 15% (n = 52) of pulmonary HLACTs reported results within 1 year of the primary completion date. According to disease group, 12.9% respiratory neoplasm, 14.8% asthma, 20% chronic obstructive pulmonary disease, and 14.9% of other pulmonary HLACTs reported results within the 1-year reporting period.
The percentage of HLACTs with reported results increased dramatically at the 1-year milestone, with gradual incremental change in the percent reporting results during the subsequent years. Among HLACTs reporting results at any time over the 5-year study period, the median (IQR) reporting time was 29 (16-47) months. When we compared cumulative reporting by disease category, the overall log-rank test identified at least one statistically significant difference between groups (p \ 0.001). Pair-wise comparisons demonstrated that neoplasm HLACTs were less likely to report results compared with ''other respiratory'' HLACTs (p \ 0.0001) or chronic obstructive pulmonary disease HLACTs (p = 0.004); asthma HLACTs were also less likely to report results than other HLACTs (p = 0.03), but were not significantly different from chronic obstructive pulmonary disease HLACTs (p = 0.07).
After reviewing the pulmonary HLACTs, we found that 141 of 1447 (9.7%) submitted a certification or extension request within 12 months of termination or completion of the study and 314 (21.7%) submitted a certification or extension request within the 5-year study period. Of the pulmonary HLACTs not reporting results during the study period, 214 of 828 (25.9%) trials potentially had a legally acceptable delay because they submitted a certification or exemption request at some time during the study period.
Pulmonary HLACTs' characteristics independently associated with lower likelihood of reporting and time trends in timely reporting
In multivariable Cox models, pulmonary HLACTs' characteristics associated with a lower likelihood of reporting results during the 5-year period included earlier HLACT phase, no FDA oversight, and having a non-NIH or non-industry funding source. As compared to phase 4 HLACTs, earlier phase HLACTs were less likely to report results: adjusted hazard ratio of 0.41 (95% confidence interval (CI): 0.31-0.54) in phases 1/2 and 2; 0.55 (95% CI: 0.42-0.72) in phases 2/3 and 3; and 0.43 (95% CI: 0.29-0.63) in phase N/A. Pulmonary HLACTs without FDA oversight were less likely to report results (adjusted hazard ratio 0.65, 95% CI: 0.51-0.83) compared to HLACTs with the FDA oversight. Industry-funded and NIH-funded HLACTs had comparable reporting, but HLACTs with other funding sources (primarily academic or non-NIH government trials) were less likely to report results (adjusted hazard ratio 0.49, 95% CI: 0.34-0.71) when compared with NIH-funded HLACTs. Differences in results reporting between disease groups were attenuated toward the null (p = 0.11) after adjustment for other trial characteristics. Trials that completed follow-up later in our study period had a slightly higher rate of reporting results than trials that completed earlier (adjusted hazard ratio 1.12 for each 1-year increment in completion year, 95% CI: 1.04-1.20). There was no evidence of interaction between disease group and study completion year for timely reporting of pulmonary HLACTs (Table 2) , suggesting that the overall improvement in results reporting during our study period was similar across disease groups.
Conclusion
In this study of 5 years of data collected through ClinicalTrials.gov, over half of all pulmonary HLACTs reported results to the ClinicalTrials.gov database since the Food and Drug Administration Amendments Act regulations were enacted in 2007. However, only 15% of pulmonary HLACTs reported results within 1 year of completion or termination, the time mandated by federal regulation. Reporting was particularly low in HLACTs evaluating interventions for asthma, earlyphase HLACTs, HLACTs without the FDA oversight, and those funded by academic institutions or other non-NIH federal agencies. Reporting improved in all disease conditions (e.g. asthma, neoplasm, chronic obstructive pulmonary disease, other) over the 5-year study period. Our findings demonstrate a need for improved reporting among pulmonary HLACTs overall and identification of specific types of studies for which efforts to improve reporting should be more focused.
Prior studies have examined reporting behaviors for all HLACTs but have not specifically focused on pulmonary HLACTs. Our findings for pulmonary HLACTs were comparable to all HLACTs for reports within 1 year of HLACTs' completion (13.4% overall vs 15% for pulmonary HLACTs), and pulmonary HLACTs fared better than the overall group for reports within our 5-year study window (38.3% overall vs 55.1% for pulmonary HLACTs). However, pulmonary HLACTs had longer median time to reporting (17 vs 29 months) when compared to reports on all HLACTs, respectively. 16 Our finding that early-phase HLACTs, HLACTs with no FDA oversight, and those with other funding sources were less likely to report results during the 5-year study period were similar to findings among all HLACTs. However, Anderson et al. also found that other intervention types (non-drug, non-device, and non-biologic) were less likely to report results during the 5-year study period in all HLACTs. 16, 24 As of 21 September 2016, the NIH and the Department of Health and Human Services have finalized policies to expand mandatory reporting of basic summary results to the ClinicalTrials.gov database. 2, 25 In the Final Rule for Clinical Trial Registration and Results, Health and Human Services requires submission of results of all Food and Drug Administration Amendments Act regulated medical products, regardless of approval status, to be reported within 1 year of trial completion. Additionally, the final rule now requires the submission of full protocol and statistical analysis plan at the time of results submission, more detailed information about adverse events (e.g. collection method and event time-frame), and requires the reporting of race and ethnicity as a part of demographic data. 2, 8, 25, 26 The NIH has expanded mandatory registration and reporting of basic summary results of all NIH-funded trials, including those not subject to the Final Rule. 8, 25, 27 Failure to comply with the Final Rule may result in civil monetary penalty actions imposed by the Food and Drug Administration Amendments Act, public disclosure of non-compliance status, and possible loss of funding for those applicable clinical trials funded by Health and Human Services. Under NIH's policy, an institution may lose funding if it cannot verify registration and results reporting from all NIH-funded trials. 2, 8, 25, 28, 29 Policies requiring results reporting have the potential to transform clinical research by enhancing transparency on the process of research and by minimizing the impact of reporting and publication bias. 30 It is well known that studies with negative findings are often not reported as conducted and often do not have their findings published.
18,31 Improved transparency regarding the conduct and outcomes of these studies could decrease the likelihood of redundant and/or unnecessary consideration of ineffective therapies and speed the pace of research and the discovery of effective clinical treatments. It could also enhance clinicians' and policy makers' capacity to make informed decisions based on all available evidence. 6, 8, 11, 32 Nonetheless, experience with these policies is relatively new, and potential disadvantages to their implementation may not yet have fully evolved. 6, 11, 16, 17, 24, [33] [34] [35] [36] Strategies to improve reporting should be centered around institutional priorities to promote awareness and compliance among clinical investigators and sponsors of research. 1, 2, 25, 37 Institutions can require ClinicalTrials.gov registration as a condition of institutional review board approval and results reporting for institutional review board renewal. To minimize the burden of data entry, institutions can create an interface to transfer data that are commonly collected during yearly process reports or institutional review board renewals. Other strategies include the International Committee of Medical Journal Editors requiring and not ''recommending'' posting of clinical trial results in a public registry. In 2004, the International Committee of Medical Journal Editors made registration in a publically accessible registry a prerequisite for publication resulting in a substantial increase in the number of trials in the ClinicalTrials.gov database. 4, 37 Our study has limitations. First, we identified HLACTs based on a National Library of Medicinebased algorithm which has been previously shown to have an estimated false-negative rate of 16%-19% and false-positive rate of 4.4%. 16 Second, some pulmonary HLACTs may have been excluded because they did not have medical subject heading terms under the Respiratory Tract Diseases subheading. Thus, it is possible we did not identify some truly eligible pulmonary HLACTs through our approach. Third, some HLACTs may not have been legally required to report summary results within 1 year because of certifications or extensions allowed through the Food and Drug Administration Amendments Act, which may have limited our accuracy in estimating compliance with the Food and Drug Administration Amendments Act. A previous study found that 6 .1% of all HLACTs not reporting results at 1 year had submitted applications for certifications and/or exemption while 12.1% not reporting at 5 years had submitted such applications. 16 Fourth, the reported hazard ratios may overestimate relative differences during the early study period and potentially underestimate differences during the latter study period due to the dramatic increase in reporting at the 1-year milestone and greater differentiation between reporting patterns of different types of studies after the 1-year mark.
In conclusion, we found suboptimal reporting of pulmonary clinical HLACTs' findings in ClinicalTrials.gov despite a federal mandate. Pulmonary investigators should be aware of the federal mandate, with special attention paid to reporting results of earlier phase HLACTs, HLACTs not requiring FDA oversight, and HLACTs with non-industry or non-NIH funding.
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